Artivion (NYSE:AORT) CEO James Mackin Sells 70,000 Shares

Artivion, Inc. (NYSE:AORT) CEO James Mackin sold 70,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total value of $2,026,500.00. Following the completion of the sale, the chief executive officer directly owned 877,275 shares of the company’s stock, valued at approximately $25,397,111.25. This represents a 7.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Artivion Stock Performance

NYSE AORT opened at $27.97 on Friday. The stock’s fifty day moving average is $24.92 and its two-hundred day moving average is $30.15. The firm has a market capitalization of $1.36 billion, a P/E ratio of -399.51 and a beta of 1.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. Artivion, Inc. has a fifty-two week low of $19.16 and a fifty-two week high of $48.25.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The business had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. On average, research analysts anticipate that Artivion, Inc. will post 0.45 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Citigroup reiterated a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Canaccord Genuity Group raised their price target on shares of Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday. Wall Street Zen lowered shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Stifel Nicolaus set a $45.00 price objective on Artivion in a report on Monday, June 1st. Finally, Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Artivion currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.83.

Institutional Investors Weigh In On Artivion

Institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new stake in Artivion in the 3rd quarter valued at approximately $27,000. Rockefeller Capital Management L.P. boosted its position in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after buying an additional 399 shares during the period. Larson Financial Group LLC grew its stake in shares of Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after buying an additional 563 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after buying an additional 538 shares in the last quarter. Finally, KBC Group NV purchased a new stake in shares of Artivion in the 4th quarter valued at $65,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.